585 related articles for article (PubMed ID: 29197930)
1. The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions.
Corton JC; Peters JM; Klaunig JE
Arch Toxicol; 2018 Jan; 92(1):83-119. PubMed ID: 29197930
[TBL] [Abstract][Full Text] [Related]
2. Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study.
Corton JC; Cunningham ML; Hummer BT; Lau C; Meek B; Peters JM; Popp JA; Rhomberg L; Seed J; Klaunig JE
Crit Rev Toxicol; 2014 Jan; 44(1):1-49. PubMed ID: 24180432
[TBL] [Abstract][Full Text] [Related]
3. PPARalpha agonist-induced rodent tumors: modes of action and human relevance.
Klaunig JE; Babich MA; Baetcke KP; Cook JC; Corton JC; David RM; DeLuca JG; Lai DY; McKee RH; Peters JM; Roberts RA; Fenner-Crisp PA
Crit Rev Toxicol; 2003; 33(6):655-780. PubMed ID: 14727734
[TBL] [Abstract][Full Text] [Related]
4. A human relevance investigation of PPARα-mediated key events in the hepatocarcinogenic mode of action of propaquizafop in rats.
Strupp C; Bomann WH; Spézia F; Gervais F; Forster R; Richert L; Singh P
Regul Toxicol Pharmacol; 2018 Jun; 95():348-361. PubMed ID: 29626562
[TBL] [Abstract][Full Text] [Related]
5. Involvement of Peroxisome Proliferator-Activated Receptor-Alpha in Liver Tumor Production by Permethrin in the Female Mouse.
Kondo M; Miyata K; Nagahori H; Sumida K; Osimitz TG; Cohen SM; Lake BG; Yamada T
Toxicol Sci; 2019 Apr; 168(2):572-596. PubMed ID: 30629241
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans.
Heintz MM; Haws LC; Klaunig JE; Cullen JM; Thompson CM
Toxicol Sci; 2023 Mar; 192(1):15-29. PubMed ID: 36629480
[TBL] [Abstract][Full Text] [Related]
7. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance.
Lai DY
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2004 May; 22(1):37-55. PubMed ID: 15845221
[TBL] [Abstract][Full Text] [Related]
8. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.
Doull J; Cattley R; Elcombe C; Lake BG; Swenberg J; Wilkinson C; Williams G; van Gemert M
Regul Toxicol Pharmacol; 1999 Jun; 29(3):327-57. PubMed ID: 10388618
[TBL] [Abstract][Full Text] [Related]
9. An Evaluation of the Human Relevance of the Liver Tumors Observed in Female Mice Treated With Permethrin Based on Mode of Action.
Kondo M; Kikumoto H; Osimitz TG; Cohen SM; Lake BG; Yamada T
Toxicol Sci; 2020 May; 175(1):50-63. PubMed ID: 32040184
[TBL] [Abstract][Full Text] [Related]
10. Characterization of peroxisome proliferator-activated receptor alpha--independent effects of PPARalpha activators in the rodent liver: di-(2-ethylhexyl) phthalate also activates the constitutive-activated receptor.
Ren H; Aleksunes LM; Wood C; Vallanat B; George MH; Klaassen CD; Corton JC
Toxicol Sci; 2010 Jan; 113(1):45-59. PubMed ID: 19850644
[TBL] [Abstract][Full Text] [Related]
11. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes.
Heintz MM; Klaren WD; East AW; Haws LC; McGreal SR; Campbell RR; Thompson CM
Toxicol Sci; 2024 Jun; 200(1):165-182. PubMed ID: 38574381
[TBL] [Abstract][Full Text] [Related]
12. Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver.
Rusyn I; Peters JM; Cunningham ML
Crit Rev Toxicol; 2006 May; 36(5):459-79. PubMed ID: 16954067
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-α activation and excess energy burning in hepatocarcinogenesis.
Misra P; Reddy JK
Biochimie; 2014 Mar; 98():63-74. PubMed ID: 24291192
[TBL] [Abstract][Full Text] [Related]
14. Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR).
Yamada T; Cohen SM; Lake BG
Crit Rev Toxicol; 2021 May; 51(5):373-394. PubMed ID: 34264181
[TBL] [Abstract][Full Text] [Related]
15. Dose and Effect Thresholds for Early Key Events in a PPARα-Mediated Mode of Action.
Lake AD; Wood CE; Bhat VS; Chorley BN; Carswell GK; Sey YM; Kenyon EM; Padnos B; Moore TM; Tennant AH; Schmid JE; George BJ; Ross DG; Hughes MF; Corton JC; Simmons JE; McQueen CA; Hester SD
Toxicol Sci; 2016 Feb; 149(2):312-25. PubMed ID: 26519955
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the mode of action of perchloroethylene-induced mouse liver tumors.
Klaunig JE; Bevan C; Gollapudi B
Toxicol Ind Health; 2024 May; 40(5):272-291. PubMed ID: 38523547
[TBL] [Abstract][Full Text] [Related]
17. A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.
Guyton KZ; Chiu WA; Bateson TF; Jinot J; Scott CS; Brown RC; Caldwell JC
Environ Health Perspect; 2009 Nov; 117(11):1664-72. PubMed ID: 20049115
[TBL] [Abstract][Full Text] [Related]
18. Characterization of nuclear receptor-mediated murine hepatocarcinogenesis of the herbicide pronamide and its human relevance.
LeBaron MJ; Rasoulpour RJ; Gollapudi BB; Sura R; Kan HL; Schisler MR; Pottenger LH; Papineni S; Eisenbrandt DL
Toxicol Sci; 2014 Nov; 142(1):74-92. PubMed ID: 25092647
[TBL] [Abstract][Full Text] [Related]
19. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Hays T; Rusyn I; Burns AM; Kennett MJ; Ward JM; Gonzalez FJ; Peters JM
Carcinogenesis; 2005 Jan; 26(1):219-27. PubMed ID: 15447978
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the role of peroxisome proliferator-activated receptor alpha (PPARalpha) in mouse liver tumor induction by trichloroethylene and metabolites.
Corton JC
Crit Rev Toxicol; 2008; 38(10):857-75. PubMed ID: 18821149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
